NovoCure Limited (NVCR)
Sells medical devices that use electric fields to slow cancer tumor growth.
$16.63-0.02%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+46.9%
The outlook
NVCR trades near the middle of its 52-week range with a Buy consensus from analysts, whose average price target sits roughly 63% above the current level. Price action is mixed relative to its moving averages, though the overall analyst lean and target suggest cautious optimism among coverage.
What’s behind the score
Analyst consensusBuy — 2.0 avg of 7 analysts
Price trendMixed vs its moving averages
52-week range59% of the way from its 52-week low to high
Price targetAvg target +63% vs current price
Analyst price target
~12-month · 7 analysts$27.14average target+63.2% vs now
Now $16.63
Low $17.00High $52.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.93B
52-wk high
$21.45
52-wk low
$9.82
50-day avg
$16.70
200-day avg
$13.76
Trailing P/E
—